CD274 and non-small cell lung carcinoma: STM2457 is also being considered for the treatment of non-small cell lung cancer (NSCLC), where it can upregulate programmed death-ligand 1 (PD-L1) both in vivo and in vitro, enhance the efficacy of NSCLC immunotherapy, and inhibit tumor progression while overcoming heterogeneity through its impact on the translatome (90).